Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial
- Galimberti, Sara
- Luminari, Stefano
- Ciabatti, Elena
- Grassi, Susanna
- Guerrini, Francesca
- Dondi, Alessra
- Marcheselli, Luigi
- Ladetto, Marco
- Piccaluga, Pier Paolo
- Gazzola, Anna
- Mannu, Claudia
- Monitillo, Luigia
- Mantoan, Barbara
- Giudice, Ilaria Del
- Starza, Irene Della
- Cavalli, Marzia
- Arcaini, Luca
- Tucci, Alessra
- Palumbo, Giuseppe Alberto
- Rigacci, Luigi
- Pulsoni, Alessro
- Vitolo, Umberto
- Boccomini, Carola
- Vallisa, Daniele
- Bertoldero, Giovanni
- Gaidano, Gianluca
- Musto, Pellegrino
- Petrini, Mario
- Federico, Massimo
DOIAbstract
PURPOSE: The role of the minimal residual disease (MRD) in follicular lymphoma is still debated. In this study, we assessed whether the BCL2/IGH rearrangement could have a prognostic role in patients receiving R-CHOP, R-FM, or R-CVP. EXPERIMENTAL DESIGN: DNAs from 415 patients among the 504 cases enrolled in the FOLL05 trial (NCT00774826) were centralized and assessed for the BCL2/IGH at diagnosis, at the end of treatment, and after 12 and 24 months. RESULTS: At diagnosis, the molecular marker was detected in 53% of cases. Patients without molecular marker or with a low molecular tumor burden (<1 7 10(-4) copies) showed higher complete remission (CR) rate and longer progression-free survival (PFS; 3-year PFS 80% vs. 59%; P = 0.015)...
Add to ORKG